Synthesis of optically active SARS-CoV-2 Mpro inhibitor drug nirmatrelvir (Paxlovid): an approved treatment of COVID-19

Synthesis of nirmatrelvir (paxlovid), an FDA approved SARS-COV-2 MPro inhibitor drug is described. The present optically active synthesis avoids a critical epimerization step.